Background: Patient-reported outcomes (PROs) are important when evaluating treatment benefits in rheumatoid arthritis (RA).
GlaxoSmithKline has announced results from a 7-year safety and efficacy continuation study for Benlysta (belimumab) in patients with active, autoantibody-positive...
Janssen Biotech announced the approval of a FDA Supplemental Biologics License Application (sBLA) for Simponi Aria (golimumab for infusion) for...